|
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease
|
22 Dec, 2022 |
|
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
|
08 Dec, 2022 |
|
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer
|
06 Dec, 2022 |
|
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
|
29 Nov, 2022 |
|
INmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of XPro1595 in Mild Alzheimer’s Disease
|
14 Nov, 2022 |
|
INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update
|
02 Nov, 2022 |
|
INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2
|
26 Oct, 2022 |
|
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune
|
19 Oct, 2022 |
|
INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference
|
07 Sep, 2022 |
|
INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update
|
03 Aug, 2022 |
|
INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3
|
27 Jul, 2022 |
|
INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease
|
25 Jul, 2022 |
|
USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases
|
22 Jun, 2022 |
|
INmune Bio, Inc. Presents Data on Combination Therapy with INB03™ on Overcoming Resistance to HER2 Targeted Therapies in Breast Cancer
|
16 Jun, 2022 |
|
INmune Bio, Inc. to Provide Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease
|
23 May, 2022 |
|
INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
|
18 May, 2022 |
|
INmune Bio, Inc. Presents Data Demonstrating XPro™ Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation
|
10 May, 2022 |
|
INmune Bio, Inc. Announces First Quarter 2022 Results and Provides Business Update
|
05 May, 2022 |
|
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
|
28 Apr, 2022 |
|
INmune Bio, Inc. to Participate at the B. Riley Neuro & Ophthalmology Conference
|
25 Apr, 2022 |
|
INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
|
13 Apr, 2022 |
|
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
|
11 Apr, 2022 |
|
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
|
04 Apr, 2022 |
|
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
|
30 Mar, 2022 |
|
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
|
25 Mar, 2022 |
|
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
|
15 Mar, 2022 |
|
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference
|
14 Mar, 2022 |
|
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
|
03 Mar, 2022 |
|
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
|
23 Feb, 2022 |
|
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
|
08 Feb, 2022 |
|
INmune Bio, Inc. Announces Research Collaboration with Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
|
25 Jan, 2022 |
|
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
|
04 Jan, 2022 |
